Aptahem announces positive biological effect in a Corona virus-induced acute lung injury model treated with Apta-1

Aptahem can today announce that in a Corona virus challenge induced Acute Lung Injury model studies with Apta-1 treatment shows strong evidence in maintaining systemic circulation, protection of vital organs, regulation of crucial cytokines and preventing hemolysis.

Research commissioned by Aptahem has, with these results, added further understanding to the multifunctional properties of Apta-1 and its broadness to handle pathogen driven inflammatory situations. The results resonating very well with the findings from the collaboration with Örebro University.

The research builds on previous studies to understand Apta-1 behavior and to optimize the study protocols for their Corona viral lung injury model. Aptahem’s third-party research partners have validated Aptahem’s own LPS studies but in their own sepsis-like acute lung injury model. This was a very important study as this model differed in many ways to Aptahem’s used systemic models. The new data confirmed Aptahem’s results, hence an important evidence for Aptahem’s claims on Apta-1 in sepsis.

Aptahem will now commission additional research to continue to analyze other samples and, together with the collaboration partner, plan next steps for a continued collaboration which will bring further clarity on Apta-1 benefits as well as will support Aptahem’s continued growth and journey into becoming a biotech company for clinical treatment.

“Collaboration with biotechnology partners is an important step in advancing academic research to its next stage of impact, potentially leading to new therapy options for patients down the road. Early studies on Apta-1 may suggest that it has protective effects on Corona viral-infection induced acute lung injury, and these intriguing findings warrant further study”, says Mingyao Liu, Professor, MD, and Senior Scientist at the Toronto General Hospital Research Institute, University Health Network; the James and Mary Davie Chair in Lung Injury, Repair and Regeneration; and a Professor of Surgery, Medicine and Physiology, and Director of Institute of Medical Science at the University of Toronto’s Temerty Faculty of Medicine.

Dr. Luiza Jedlina, CSO at Aptahem, comments: “We are delighted to see the outcome of this study and how it resonates with our own studies and other collaborations” and she continues: ”This virus driven model confirms our view on Apta-1’s uniqueness and we will continue to further explore its multifunctional capabilities”

For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com

Forward-looking statements
This press release contains forward-looking statements that constitute subjective estimates and forecasts about the future. Assessments about the future are only valid on the date they are made and are, by their nature, similar to research and development work in the biotech field, associated with risk and uncertainty. In light of this, actual outcomes may differ substantially from what is described in this press release.

About Aptahem
Aptahem AB (APTA) is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in sepsis patients, among others. The company possesses patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.